GlassScriptPhysician profile
Sardar Z Imam
NPI 1962799775
$24,471.30
in general payments reported to CMS, 2019-2025
42 companies · $43.43 in 2025
The $43.43 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,011 · 2020: $3,535 · 2021: $7,510 · 2022: $2,550 · 2023: $5,471 · 2024: $2,352 · 2025: $43.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,843 · Travel and Lodging: $1,519 · Food and Beverage: $449 · Education: $55.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,842.50 |
| Travel and Lodging | $1,518.59 |
| Food and Beverage | $449.10 |
| Education | $55.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,852.42 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $2,940.00 | 2022-2023 | Darzalex |
| Pfizer INC. | $2,745.21 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,555.18 | 2019-2024 | |
| Exelixis INC. | $2,309.35 | 2019-2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $2,250.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $2,100.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,819.68 | 2019-2023 | Imfinzi |
| Seagen INC. | $1,411.35 | 2021-2023 | Padcev |
| Janssen Biotech, INC. | $1,091.80 | 2019-2023 | Erleada, Imbruvica |
| Daiichi Sankyo INC. | $550.00 | 2022 | |
| Genentech USA, INC. | $122.87 | 2019-2023 | Venclexta, Phesgo |
| Merck Sharp & Dohme LLC | $112.33 | 2019-2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $107.78 | 2019-2024 | Augtyro |
| Celgene Corporation | $70.96 | 2019-2024 | Reblozyl |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.03 | 2019 | |
| Gilead Sciences, INC. | $40.44 | 2019-2023 | Trodelvy |
| Genzyme Corporation | $36.58 | 2019-2020 | |
| Roche Diagnostics Corporation | $35.71 | 2020 | |
| Lilly USA, LLC | $31.05 | 2019 | |
| Eisai INC. | $21.38 | 2019 | |
| Taiho Oncology, INC. | $21.02 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.59 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.89 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.05 | 2019 | |
| Amgen INC. | $17.87 | 2019 | |
| Spectrum Pharmaceuticals INC. | $17.63 | 2023 | Rolvedon |
| Rigel Pharmaceuticals, INC. | $17.10 | 2019 | |
| Array Biopharma INC | $16.66 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.96 | 2020 | |
| Novocure INC. | $15.32 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.45 | 2019 | |
| Emd Serono, INC. | $11.64 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sardar Imam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.